Source:http://linkedlifedata.com/resource/pubmed/id/20674353
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
17
|
pubmed:dateCreated |
2010-8-16
|
pubmed:abstractText |
The resistance to methotrexate by a number of cancer cells such as breast cancer cell-line MDA-MB-231 due to poor permeability renders it less effective as an anticancer agent for these cells. Proline prodrug of methotrexate (Pro-MTX) was designed as a substrate of prolidase which is specific for imido bond of dipeptide containing proline and expected to penetrate MDA-MB-231 cells more efficiently. The prodrug was synthesized by solid-phase peptide synthesis method and examined as a substrate of pure prolidase as well as cell homogenate. The cytotoxicity against MDA-MB-231 and non-methotrexate resistant breast cancer cell line, MCF-7 was also examined by XTT assay. The results showed that Pro-MTX was a substrate of prolidase. It was also shown that the prodrug could be converted to parent drug methotrexate in Caco-2 and HeLa cell homogenate. When tested with Caco-2 and MCF-7 cells, Pro-MTX showed weaker cytotoxicity compared with methotrexate. But for methotrexate resistant MDA-MB-231 cells, Pro-MTX showed stronger activity than methotrexate. The results indicated that the proline prodrug of methotrexate may overcome the resistance of human breast cancer cells in culture.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1464-3405
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2010 Elsevier Ltd. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:day |
1
|
pubmed:volume |
20
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
5108-12
|
pubmed:meshHeading |
pubmed-meshheading:20674353-Antimetabolites, Antineoplastic,
pubmed-meshheading:20674353-Breast Neoplasms,
pubmed-meshheading:20674353-Cell Line, Tumor,
pubmed-meshheading:20674353-Drug Resistance, Neoplasm,
pubmed-meshheading:20674353-Humans,
pubmed-meshheading:20674353-Methotrexate,
pubmed-meshheading:20674353-Prodrugs,
pubmed-meshheading:20674353-Proline
|
pubmed:year |
2010
|
pubmed:articleTitle |
Development of methotrexate proline prodrug to overcome resistance by MDA-MB-231 cells.
|
pubmed:affiliation |
Division of Pharmaceutical Sciences, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 11201, USA. james.wu@liu.edu
|
pubmed:publicationType |
Journal Article
|